Search Result

Results for "

non-small-cell

" in MedChemExpress (MCE) Product Catalog:

By Targets:	NAMPT (1) Tim3 (1) ADC Antibody (1) Akt (14) AMPK (1) Amyloid-β (2) Anaplastic lymphoma kinase (ALK) (2) Antifolate (2) Apoptosis (33) ATTECs (1) Aurora Kinase (1) Autophagy (12) Bacterial (3) Biochemical Assay Reagents (2) BMX Kinase (1) Btk (1) c-Fms (1) c-Met/HGFR (9) Carbonic Anhydrase (1) Caspase (2) CCR (1) CDK (3) COX (1) CTLA-4 (2) Dihydrofolate reductase (DHFR) (1) Discoidin Domain Receptor (1) DNA-PK (2) DNA/RNA Synthesis (3) Drug Metabolite (1) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (1) EGFR (57) Endogenous Metabolite (2) Epigenetic Reader Domain (1) ERK (2) FAK (3) FAP (1) Ferroptosis (3) Fluorescent Dye (1) GSK-3 (1) HIF/HIF Prolyl-Hydroxylase (2) Histone Demethylase (1) Histone Methyltransferase (3) HSP (3) IFNAR (1) IKK (1) Immune Checkpoint (1) Interleukin Related (1) Isotope-Labeled Compounds (1) JNK (1) Macrophage migration inhibitory factor (MIF) (1) MAP4K (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (3) MEK (1) mGluR (1) Microtubule/Tubulin (3) Mitophagy (2) MMP (1) Monoamine Oxidase (1) mTOR (3) Opioid Receptor (2) P2X Receptor (1) p38 MAPK (3) PARP (1) PD-1/PD-L1 (8) PDGFR (1) Phosphatase (1) Phosphodiesterase (PDE) (2) PI3K (6) PINK1/Parkin (2) PKC (1) Polo-like Kinase (PLK) (1) PPAR (2) Prostaglandin Receptor (1) PROTACs (4) Pyroptosis (2) RAD51 (2) Ras (6) Reactive Oxygen Species (3) RET (2) ROCK (1) ROR (1) ROS Kinase (2) Src (1) STAT (1) Survivin (1) TAM Receptor (4) TNF Receptor (1) Toll-like Receptor (TLR) (2) Topoisomerase (1) Trk Receptor (1) TROP2 (1) TrxR (1) ULK (1)
By Research Areas:	Cancer (176) Cardiovascular Disease (2) Endocrinology (1) Infection (5) Inflammation/Immunology (19) Metabolic Disease (1) Neurological Disease (2)
Click Chemistry:	Alkynes (2)

176

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: Small Interfering RNA (siRNA) Itk TOPK NAMPT ALCAM/CD166 GDNF Receptor VISTA BCL6 Tim3 BMI1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-157912

EGFR-IN-102	EGFR	Cancer
EGFR-IN-102 (compound 6) is an oral active EGFR inhibitor with the IC₅₀ of 2 nM, and can be used for study of non-small-cell lung cancer .

HY-164464

BPI-15086	EGFR	Cancer
BPI-15086 an orally active, potent, irreversible mutant-selective inhibitor of both EGFR and T790M resistance mutations tyrosine kinase. BPI-15086 can be used for the research of non-small-cell lung cancer .

HY-142283CS

N-Methyl-dosimertinib-d5	EGFR	Cancer
N-Methyl-dosimertinib-d₅ is the deuterium labeled of Dosimertinib (HY-142283). Dosimertinib is a highly potent, selective, and orally active deuterated EGFR inhibiotor. Dosimertinib can be used for the research of non-small-cell lung cancer[1][2].

HY-142283BS

N-Desmethyl dosimertinib-d5	EGFR	Cancer
N-Desmethyl dosimertinib-d₅ is the deuterium labeled Dosimertinib (HY-142283). Dosimertinib is a highly potent, selective, and orally active deuterated EGFR inhibiotor. Dosimertinib can be used for the research of non-small-cell lung cancer[1][2].

HY-145844

EGFR-IN-44	EGFR Apoptosis	Cancer
EGFR-IN-44 (Compound 6a) is a potent, orally active EGFR tyrosine kinase inhibitor with an IC₅₀ of 4.11 nM. EGFR-IN-44 induces cell apoptosis and shows an oral bioavailability value of 33.57%. EGFR-IN-44 can be studied for non-small-cell lung cancers .

HY-154960

Tubulin/AKT1-IN-1	Akt Apoptosis Microtubule/Tubulin	Cancer
Tubulin/AKT1-IN-1 (Compound D1-1) is an inhibitor of tubulin polymerization and AKT pathway activation. Tubulin/AKT1-IN-1 significantly inhibits the proliferation and metastasis of H1975 cells and slightly induced their apoptosis and can be used for non-small-cell lung cancer (NSCLC) research .

HY-163417

HER2-IN-15	EGFR	Cancer
HER2-IN-15 (Compound 1) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-15 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163418

HER2-IN-17	EGFR	Cancer
HER2-IN-17 (Compound 2) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-17 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-163420

HER2-IN-16	EGFR	Cancer
HER2-IN-16 (Compound 14) is an inhibitor for HER2, which inhibits the Her YVMA exon 20 insertion mutation (HER2 YVMA) with an IC₅₀ <200 nM. HER2-IN-16 inhibits proliferation of HER2 YVMA mutated BaF3 cells with an IC₅₀ <200 nM and amliorates non-small-cell lung cancer (NSCLC) .

HY-164487

JBJ-08-178-01	EGFR	Cancer
JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer .

HY-12972

Mavelertinib PF-06747775	EGFR	Cancer
Mavelertinib is a selective, orally available and irreversible EGFR tyrosine kinase inhibitor (EGFR TKI), with IC₅₀s of 5, 4, 12 and 3 nM for Del, L858R, and double mutants T790M/L858R and T790M/Del, respectively. Mavelertinib can be used for the research of non-small-cell lung cancer (NSCLC) .

HY-167948

Dacomitinib metabolite M1/2	Others	Cancer
Dacomitinib metabolite M1/2 is a potent inhibitor of both wild-type (WT) EGFR and the T790M mutation, demonstrating significant activity against acquired resistance mechanisms in EGFR-mutant non-small-cell lung cancer (NSCLC).

HY-149841

AKT-IN-17	Akt	Cancer
AKT-IN-17 is a AKt inhibitor. AKT-IN-17 inhibits AKt in A549 cells, leading to Apoptosis. AKT-IN-17 can be used in non-small cell lung cancer study .

HY-14389

LP-261	Microtubule/Tubulin	Cancer
LP-261 is a potent and orally active anti-mitotic agent and shows an inhibition of in vitro tubulin polymerization with an EC₅₀ of 3.2 μM . LP-261 inhibits growth of a human non-small-cell lung tumor (NCI-H522) in vivo and can be used for cancer research .

HY-149842

AKT-IN-18	Akt Apoptosis	Cancer
AKT-IN-18, an inhibitor of Akt, inhibits Akt with an IC₅₀ of 69.45 μΜ in A549 cells. AKT-IN-18 induces apoptosis and can be used in non-small cell lung cancer study .

HY-13617

Edatrexate CGP 30694	Antifolate	Cancer
Edatrexate (CGP 30694), as known as 10-Ethyl-10-deazaaminopterin, is Methotrexate (HY-14519) analog, exhibits antitumor activity against MTX-resistant tumors. Edatrexate is an antifolate antimetabolite, can be used for reasearch of non-small-cell lung cancer, breast cancer, non-Hodgkin's lymphoma, and cancer of the head and neck .

HY-142283AS

Dosimertinib mesylate	EGFR	Cancer
Dosimertinib-d₅ (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d₅ (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₅ (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d₅ (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

HY-148510

HKB99	Phosphatase	Cancer
HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1). HKB99 inhibits the formation of invasive pseudopodia and increases the level of PAI-2 in vitro. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC) .

HY-168112

EGFR-IN-127	EGFR	Cancer
EGFR-IN-127 is an ATP-competitive EGFR inhibitor with IC₅₀s of 136.3 nM and 161. 2 nM for EGFR ^del19 and EGFR ^{del19/T790M/C797S}, respectively. EGFR-IN-127 has the potential for the study of non-small-cell lung cancer (NSCLC) .

HY-149840

Antitumor agent-113	Apoptosis	Cancer
Antitumor agent-113 shows cytotoxic effects on A549 cells with IC₅₀ value of 46.60 μM and induces apoptosis. Antitumor agent-113 can be used in non-small cell lung cancer study .

HY-138072

EMI1	EGFR	Cancer
EMI1 is an EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S inhibitor. EMI1 can be used for the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC) .

HY-110088

SCH529074 1 Publications Verification	MDM-2/p53	Cancer
SCH529074 is a potent and orally active p53 activator. SCH529074 binds specifically and conformation-dependently to p53 DBD ( DNA binding domain) with a K_i of 1-2 μM in a saturable manner. SCH529074 restores mutant p53 function and interrupts HDM2-mediated ubiquitination of wild Type p53. SCH529074 can be used for the study of non-small-cell lung carcinoma (NSCLC) .

HY-142283

Dosimertinib	Isotope-Labeled Compounds EGFR	Cancer
Dosimertinib-d₃-d₃ is a potent and orally active EGFR inhibitor. Dosimertinib-d₃-d₃ decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₃-d₃ shows antiproliferative and anti-tumor activity. Dosimertinib-d₃-d₃ has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

HY-107008

SW 71425	Others	Cancer
SW 71425 inhibits cell growth against breast, colon, non-small cell lung, and ovarian tumors. .

HY-P99052

Tislelizumab 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

HY-59137

1-Methylimidazole	Others	Cancer
1-Methylimidazole can be used as a ligand for ruthenium (II) complexes in the study of non-small cell lung cancer .

HY-19637

SW044248	Topoisomerase	Cancer
SW044248 is a non-canonical topoisomerase I inhibitor, and selectively toxic for certain non-small cell lung cancer (NSCLC) cell lines.

HY-148053

Rezivertinib analogue 1	Drug Metabolite	Cancer
Rezivertinib analogue 1 is a process impurity of osimertinib mesylate. Rezivertinib analogue 1 can be used in the study of non-small cell lung cancer .

HY-151571

ZG1077	Ras	Cancer
ZG1077 is a covalent KRAS G12C inhibitor. ZG1077 can be used in the research of non-small cell lung cancer (NSCLC) .

HY-P5005

VIPhyb	Biochemical Assay Reagents	Cancer
VIPhyb (compound VIPhyb) is a vasoactive intestinal polypeptide (VIP) receptor antagonist that can be used in the study of cancers such as non-small cell lung cancer (NSCLC) .

HY-129976

Pemetrexed tromethamine (dihydrochloric) dihydrate	Others	Cancer
Pemetrexed tromethamine dihydrochloric dihydrate is a chemotherapy drug used to treat pleural mesothelioma and non-small cell lung cancer, exhibiting potent anti-cancer activity.

HY-N12690

Withaphysalin E	Others	Cancer
Withaphysalin E is a natural product that can be isolated from Physalis divericata. Withaphysalin E can be used in the study of non-small cell lung cancer .

HY-P9903

Nivolumab 15+ Cited Publications BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-153943

DNA-PK-IN-10	DNA-PK	Cancer
DNA-PK-IN-10 is a DNA-PK inhibitor. DNA-PK-IN-10 can be used for the research of breast cancer and non-small cell lung cancer .

HY-118263

Dacomitinib hydrate 20+ Cited Publications PF-00299804 hydrate; PF-299804 hydrate	EGFR	Cancer
Dacomitinib (PF-00299804) hydrate is an orally active, irreversible pan-ErbB inhibitor. Dacomitinib hydrate can be used in the research of cancers such as metastatic non-small cell lung cancer (NSCLC) .

HY-106618

Mopidamol RA 233	Phosphodiesterase (PDE)	Cancer
Mopidamol (RA 233), a derivative of Dipyridamole (HY-B0312), is a phosphodiesterase inhibitor. Mopidamol can be used for non-small cell lung cancer (N-SCLC) research .

HY-P99269

Sibrotuzumab BIBH 1; Anti-Human FAP Recombinant Antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

HY-157043

Antibacterial agent 161 trifluoromethanesulfonate	Bacterial	Infection
Antibacterial agent 161 trifluoromethanesulfonate (Compound 6) has antibacterial activity. Antibacterial agent 161 trifluoromethanesulfonate has high antiproliferative effects against colon cancer and non-small cell lung cancer .

HY-155163

APG-2449	Anaplastic lymphoma kinase (ALK) ROS Kinase FAK	Others Cancer
APG-2449 is an orally active ALK/ROS1/FAK inhibitor. APG-2449 shows antitumor activity in mouse models of non-small cell lung cancer (NSCLC) .

HY-167938

(E/Z)-PG-11047 (E/Z)-CGC-11047	Others	Cancer
(E/Z)-PG-11047 ((E/Z)-CGC-11047) is a polyamine analog with potential application in lung cancer inhibition. (E/Z)-PG-11047 effectively inhibited the growth of non-small cell and small cell lung cancer cells. (E/Z)-PG-11047 exhibits significant biochemical effects in non-small cell lung cancer cells, resulting in significant downregulation of polyamine synthetase activity. (E/Z)-PG-11047 induces polyamine metabolism, resulting in a significant reduction in polyamine levels .

HY-137433

Befotertinib 1 Publications Verification D-0316	EGFR	Cancer
Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC) .

HY-P99223

Tovetumab MEDI-575	PDGFR	Cancer
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .

HY-127079

Epothilone F	Microtubule/Tubulin	Cancer
Epothilone F is a Microtubule/Tubulin-stabilizing agent with anti-tumor activity. Epothilone F inhibits the proliferation of breast cancer cells, non-small cell lung cancer cells, drug-resistant ovarian cancer cells .

HY-169269

PROTAC SMARCA2 degrader-18	PROTACs Epigenetic Reader Domain	Cancer
PROTAC SMARCA2 degrader-18 (Example144) is a PROTAC SMARCA2 degrader. PROTAC SMARCA2 degrader-18 has the potential for the research of non-small cell lung cancer (NSCLC) .

HY-109061

Lazertinib 1 Publications Verification YH25448; GNS-1480	EGFR	Cancer
Lazertinib (YH25448) is a potent, highly mutant-selective, blood-brain barrier permeable, orally available and irreversible third-generation EGFR tyrosine kinase inhibitor, and can be used in the research of non-small cell lung cancer .

HY-111237

Butyrolactone I Olomoucin	CDK	Cancer
Butyrolactone I is an ATP-competitive inhibitor of CDK1 as a secondary metabolite from A. terreus . Butyrolactone I has antitumor effects in non-small cell lung, small cell lung, and prostate cancer cell lines .

HY-N11912

Soladulcoside A	Biochemical Assay Reagents	Cancer
Soladulcoside A is a steroidal glycoside and antineoplastic agent that can be obtained from the whole plant of Solanum nigrum. Soladulcoside A can inhibit A549 cells and has the potential to study cancers such as non-small cell lung cancer (NSCLC) .

HY-110335

OXA-06 hydrochloride	ROCK	Cancer
OXA-06 hydrochloride is an ATP-competitive ROCK inhibitor that blocks anchorage-dependent growth and invasion of non-small cell lung cancer cell lines. OXA-06 hydrochloride inhibits cofilin phosphorylation but does not stimulate apoptosis .

HY-19642A

Glesatinib hydrochloride 2 Publications Verification MGCD265 hydrochloride	TAM Receptor c-Met/HGFR	Cancer
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) .

HY-112870A

Firmonertinib mesylate 3 Publications Verification Alflutinib mesylate; Furmonertinib mesylate; AST2818 mesylate	EGFR	Cancer
Firmonertinib (Alflutinib) mesylate is is a potent inhibitor of EGFR. Firmonertinib mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Firmonertinib has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC) .

Cat. No.	Product Name

HY-L075

Anti-Lung Cancer Compound Library

1,933 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1,933 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Cat. No.	Product Name	Target	Research Area

HY-P5005

VIPhyb	Biochemical Assay Reagents	Cancer
VIPhyb (compound VIPhyb) is a vasoactive intestinal polypeptide (VIP) receptor antagonist that can be used in the study of cancers such as non-small cell lung cancer (NSCLC) .

HY-156002

LUNA18	Ras ERK	Cancer
LUNA18 is an orally-available cyclic peptide KRAS and ERK inhibitor. LUNA18 phosphorylates ERK and AKT and decreases cell proliferation in RAS-mutated cancer cells. LUNA18 exhibits RAS signal inhibition and potent anti-cancer activities through inhibiting interaction between RAS and guanine nucleotide exchange factors (GEFs) in a mouse xenograft model. LUNA18 shows significant cellular efficacy against cell lines with KRAS genetic alterations, such as colon cancer, stomach cancer, non-small cell lung cancer and pancreaticcancer .

Cat. No.	Product Name	Target	Research Area

HY-P99279

Bavituximab Anti-Human Phosphatidylserine Recombinant Antibody	Inhibitory Antibodies	Cancer
Bavituximab (Anti-Human Phosphatidylserine Recombinant Antibody) is a phosphatidylserine (PS)-targeting monoclonal antibody, suppresses tumor growth by targeting tumor vasculature and reactivating antitumor immunity. Bavituximab plus Paclitaxel (HY-B0015) and Carboplatin (HY-17393), have enhanced inhibition on non-small-cell lung cancer .

HY-P99052

Tislelizumab 2 Publications Verification	PD-1/PD-L1	Inflammation/Immunology Cancer
Tislelizumab is a monoclonal antibody that specifically binds to programmed cell death receptor 1 (PD-1), blocking its interaction with programmed death ligand 1 (PD-L1) and programmed death ligand 2 (PD-L2). Tislelizumab can reactivate immune cells such as T lymphocytes and enhance anti-tumor activity. Tislelizumab can be used for the research of a variety of tumors including typical Hodgkin's lymphoma, urothelial carcinoma, non-small cell lung cancer and hepatocellular carcinoma .

HY-P9903

Nivolumab Maximum Cited Publications 20 Publications Verification BMS-936558; ONO-4538; MDX-1106	PD-1/PD-L1	Cancer
Nivolumab is a programmed death receptor-1 (PD-1) blocking human IgG4 antibody to treat advanced (metastatic) non-small cell lung cancer.

HY-P99202

Vibostolimab	Inhibitory Antibodies	Cancer
Vibostolimab is an anti-TIGIT (*T cell* immunoglobulin and ITIM domain*) monoclonal antibody. Vibostolimab shows antitumor activity, and can be used in non-small* cell lung cancer (NSCLC) and melanoma research .

HY-P99269

Sibrotuzumab BIBH 1; Anti-Human FAP Recombinant Antibody	FAP	Cancer
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .

HY-P99223

Tovetumab MEDI-575	PDGFR	Cancer
Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC) .

HY-P99827

Cobolimab TSR-022; GSK4069889	Tim3	Cancer
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC₅₀ value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P9986

Tiragolumab MTIG-7192A; RG-6058	Inhibitory Antibodies	Inflammation/Immunology Cancer
Tiragolumab is an immune checkpoint inhibitor binding to T-cell immunoglobulin and ITIM domain (TIGIT). Tiragolumab, alone or in combination with the PD-L1 inhibitor Atezolizumab (HY-P9904), may be effective against multiple solid malignancies-most notably non-small cell lung cancer (NSCLC) .

HY-P99843

Datopotamab	TROP2 ADC Antibody	Cancer
Datopotamab (CDP7657) is a humanized anti trophoblast cell surface antigen 2 (TROP2) antibody. Datopotamab can generate antibody drug conjugates (ADC) (HY-141598) with DNA topoisomerase I inhibitor Deruxtecan (HY-13631E). Datopotamab can be used in the study of triple negative breast cancer and non-small cell lung cancer .

HY-P99275

Patritumab 1 Publications Verification Human Anti-ERBB3 Recombinant Antibody	EGFR Akt ERK PARP Survivin	Cancer
Patritumab (Human Anti-ERBB3 Recombinant Antibody) is a neutralizing monoclonal antibody to ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors .

HY-P99189

Cixutumumab IMC-A12; NSC742460	Inhibitory Antibodies	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-P99048

Sintilimab IBI308	PD-1/PD-L1	Inflammation/Immunology Cancer
Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a K_D value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer .

HY-P99809

Quavonlimab MK-1308	CTLA-4	Cancer
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody .

HY-P99117

Cadonilimab AK104	PD-1/PD-L1 CTLA-4 Immune Checkpoint	Inflammation/Immunology Cancer
Cadonilimab (AK104) is a humanized tetravalent IgG1 bispecific antibody targeting PD1/CTLA4. Cadonilimab blocks both PD-1 and CTLA-4 pathways, thereby relieving their corresponding immunosuppressive effects and reversing tumor specific T cell exhaustion. Cadonilimab significantly downregulates Fc-mediated effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement dependent cytotoxicity (CDC). Cadonilimab can be used for research of metastatic cervical cancer, as well as other malignancies such as gastric cancer, GEJ adenocarcinoma and non-small cell lung cancer (NSCLC) .

HY-P99108

Penpulimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Penpulimab is an IgG1 backbone anti-PD-1 monoclonal antibody with antitumor activities .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12690

Withaphysalin E	Structural Classification Physalis divaricata Source classification Solanaceae Plants Steroids	Others
Withaphysalin E is a natural product that can be isolated from Physalis divericata. Withaphysalin E can be used in the study of non-small cell lung cancer .

HY-N6252

Gypenoside XLVI 1 Publications Verification	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Gynostemma pentaphyllum (Thunb.) Makino Cancer	Others
Gypenoside XLVI is one of the major dammarane-type triterpenoid saponins from Gynostamma pentaphallum . Gypenoside XLVI has a tetracyclic triterpene structure and possess potent non-small cell lung carcinoma A549 cell inhibitory activity .

HY-N6871

Abietic acid	Infection Structural Classification Colophony Classification of Application Fields Pinaceae Ketones, Aldehydes, Acids Metabolic Disease Plants Inflammation/Immunology Disease Research Fields	Bacterial IKK Ferroptosis
Abietic acid, an orally active diterpene isolated from Colophony, displays significant anti-proliferative, anti-inflammatory, anti-obesity effect, bacteriostatic, cell cycle arresting and pro-apoptotic activities. Abietic acid inhibits lipoxygenase activity for allergy. Abietic acid enhances cell migration and tube formation in HUVECs. Abietic acid induces significant angiogenic potential, which is associated with upregulation of extracellular signal-regulated kinase (ERK) and p38 expression. Abietic acid attenuates sepsis-induced lung injury by inhibiting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway to inhibit M1 macrophage polarization. Abietic acid exhibits a positive effect against liver injury by attenuating inflammation and ferroptosis. Abietic acid shows accelerated wound closure in a mouse model of cutaneous wounds. Abietic acid significantly reduces the proliferation and growth of NSCLC cells by IKKβ inhibition.Additionally, Abietic acid ameliorates psoriasis-like inflammation and modulates gut microbiota in mice. Abietic acid is promising for research in non-small-cell lung cancer (NSCLC), liver injury-related deseases and psoriasis .

HY-N0816

Polyphyllin VI 3 Publications Verification	Structural Classification other families Classification of Application Fields Source classification Plants Disease Research Fields Steroids Cancer	Apoptosis Pyroptosis
Polyphyllin VI, an active saponin, possess anti-cancer activities. Polyphyllin VI induces G2/M cell cycle arrest and triggers apoptosis. Polyphyllin VI induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer .

HY-N0164

Matrine Maximum Cited Publications 12 Publications Verification Matridin-15-one; Vegard; α-Matrine	Structural Classification Classification of Application Fields Source classification Sophora flavescens Aiton Plants Biological Pesticide Research Agricultural Research Alkaloids Piperidine Alkaloids Leguminosae Inflammation/Immunology Disease Research Fields Cancer	PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis
Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-N0234

Bavachinin 3 Publications Verification 7-O-Methylbavachin; Bavachinin A	Structural Classification Monophenols Flavonoids Classification of Application Fields Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants Inflammation/Immunology Disease Research Fields	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N11912

Soladulcoside A	Structural Classification Source classification Solanum nigrum Linn. Plants Solanaceae Steroids	Biochemical Assay Reagents
Soladulcoside A is a steroidal glycoside and antineoplastic agent that can be obtained from the whole plant of Solanum nigrum. Soladulcoside A can inhibit A549 cells and has the potential to study cancers such as non-small cell lung cancer (NSCLC) .

HY-N13164

Polygalacin D3	Triterpenes Structural Classification Terpenoids Platycodon grandiflorus (Jacq.) A. DC. Source classification Campanulaceae Plants	PI3K Akt Apoptosis
Polygalacin D3 is a triterpenoid saponin compound that can be extracted from the roots of the balloon flower. Polygalacin D3 can inhibit the proliferation of non-small cell lung cancer (NSCLC) cell lines by blocking the PI3K/Akt pathway, and it induces cell cycle arrest and cell apoptosis .

HY-N1930

(-)-Hinesol Hinesol	Structural Classification Natural Products Plants Compositae Erythrina sigmoidea Hua	Apoptosis
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .

HY-N3764

Diosbulbin C	Structural Classification Terpenoids Source classification Diterpenoids Plants Dioscorea bulbifera Linn. Dioscoreaceae	Akt Dihydrofolate reductase (DHFR) Endogenous Metabolite
Diosbulbin C is a diterpene lactone component, which can be extracted from traditional Chinese medicine Dioscorea bulbifera L.. Diosbulbin C possesses high anticancer activity in non-small cell lung cancer (NSCLC). Diosbulbin C could induce cell cycle arrest at G0/G1 phase in NSCLC. Diosbulbin C also inhibits the proliferation of NSCLC cells, possibly by downregulating the expression/activation of AKT, DHFR, and TYMS .

HY-N0164R

Matrine (Standard)	Alkaloids Piperidine Alkaloids Structural Classification Leguminosae Source classification Sophora flavescens Aiton Plants	PINK1/Parkin Opioid Receptor Autophagy Mitophagy Ferroptosis Apoptosis
Matrine (Standard) is the analytical standard of Matrine. This product is intended for research and analytical applications. Matrine (Matridin-15-one) is an alkaloid found in plants from the Sophora genus that can act as a kappa opioid receptor and u-receptor agonist. Matrine has a variety of pharmacological effects, including anti-cancer, anti-oxidative stress, anti-inflammation and anti-apoptosis effects. Matrine is potential in the research of disease like human non-small cell lung cancer, hepatoma, papillary thyroid cancer and acute kidney injury (AKI) .

HY-138098

Sartorypyrone B	Triterpenes Microorganisms Classification of Application Fields Terpenoids Source classification Disease Research Fields Cancer	Others
Sartorypyrone B is a 2β-acetoxyl analogue of chevalone C. Sartorypyrone B is yielded from the ethyl acetate extract of the culture of the marine sponge-associated fungus Neosartorya tsunodae (KUFC 9213). Sartorypyrone B exhibits strong growth inhibitory activity, having GI₅₀s of 17.8, 20.5, and 25.0 μM, respectively, for MCF-7, NCI-H460, and A375-C5. Sartorypyrone B has the potential for the research of breast adenocarcinoma, non-small cell lung cancer, and melanoma diseases .

HY-N0234R

Bavachinin (Standard)	Structural Classification Monophenols Flavonoids Leguminosae Flavonones Source classification Phenols Psoralea corylifolia L. Plants	Amyloid-β PPAR HIF/HIF Prolyl-Hydroxylase
Bavachinin (Standard) is the analytical standard of Bavachinin. This product is intended for research and analytical applications. Bavachinin is agonist of pan-peroxisome proliferator-activated receptor (PPAR), with the IC₅₀ value of 21.043 μM, 12.819 μM, and 0.622 μM to PPAR-α, RRAR-β/δ, and PPAR-γ, respectively. Bavachinin is an inhibitor of HIF-1α. Bavachinin exhibits antitumor activity against non-small cell lung cancer by targeting RRAR-γ. Bavachinin is a natural compound with anti-inflammatory and anti-angiogenic activities. Bavachinin has orally bioactivity. .

HY-N13176

Stellettin B	Triterpenes Structural Classification Terpenoids Marine natural products Source classification Sponge	Autophagy Apoptosis PI3K Akt mTOR FAK
Stellettin B is a triterpenoid compound that can be isolated from the marine sponge Jaspis stellifera. Stellettin B induces G1 phase arrest, apoptosis, and autophagy in human non-small cell lung cancer A549 cells by blocking the PI3K/Akt/mTOR pathway. Stellettin B can reduce the migration and invasion of liver cancer cells by decreasing the activation of the MAPK and FAK/PI3K/AKT/mTOR signaling pathways. Stellettin B can be used in the study of various tumors .

HY-N3980

Guaiol Champacol; Guaiac alcohol	Infection Structural Classification Natural Products Classification of Application Fields Source classification Distemonanthus benthamianus Baill. Plants Compositae Disease Research Fields	Autophagy RAD51
Guaiol is a sesquiterpenoid alcohol with oral activity found in various traditional Chinese medicines, exhibiting biological activities such as anti-proliferative, autophagy-promoting, insecticidal, anti-anxiety, anti-inflammatory, diuretic, and blood pressure-lowering effects. Guaiol induces apoptosis in non-small cell lung cancer cells by regulating the stability of RAD51 through autophagy modulation. Guaiol can also act directly on parasites, inhibiting their growth by affecting the kinetoplast, mitochondrial matrix and plasma membrane of the promastigotes. Guaiol kills amastigotes at an IC₅₀ of 0.01 µg/mL. Guaiol can be used in research related to cancer, infections, cardiovascular diseases, and inflammatory conditions ^[4]

HY-N3980R

Guaiol (Standard)	Structural Classification Natural Products Source classification Distemonanthus benthamianus Baill. Plants Compositae	Autophagy RAD51
Guaiol (Standard) is the analytical standard of Guaiol. This product is intended for research and analytical applications. Guaiol is a sesquiterpenoid alcohol with oral activity found in various traditional Chinese medicines, exhibiting biological activities such as anti-proliferative, autophagy-promoting, insecticidal, anti-anxiety, anti-inflammatory, diuretic, and blood pressure-lowering effects. Guaiol induces apoptosis in non-small cell lung cancer cells by regulating the stability of RAD51 through autophagy modulation. Guaiol can also act directly on parasites, inhibiting their growth by affecting the kinetoplast, mitochondrial matrix and plasma membrane of the promastigotes. Guaiol kills amastigotes at an IC50 of 0.01 µg/mL. Guaiol can be used in research related to cancer, infections, cardiovascular diseases, and inflammatory conditions [4]

HY-108016

Peruvoside Encordin	Apocynaceae Triterpenes Structural Classification Terpenoids Source classification Thevetia peruviana (Pers.) K. Schum. Plants	Src PI3K JNK STAT EGFR Apoptosis Autophagy
Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib .

Cat. No.	Product Name	Chemical Structure

HY-142283AS

Dosimertinib mesylate
Dosimertinib-d₅ (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d₅ (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₅ (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d₅ (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

HY-19939S

VX-984 4 Publications Verification
VX-984 is an orally active, potent, selective and BBB-penetrated DNA-PK inhibitor. VX-984 efficiently inhibits NHEJ (non-homologous end joining) and increases DSBs (DNA double-strand breaks). VX-984 can be used for glioblastomas (GBM) and non-small cell lung cancer (NSCLC) research. VX-984 is a de novo deuterium .

HY-142283CS

N-Methyl-dosimertinib-d5
N-Methyl-dosimertinib-d₅ is the deuterium labeled of Dosimertinib (HY-142283). Dosimertinib is a highly potent, selective, and orally active deuterated EGFR inhibiotor. Dosimertinib can be used for the research of non-small-cell lung cancer[1][2].

HY-142283BS

N-Desmethyl dosimertinib-d5
N-Desmethyl dosimertinib-d₅ is the deuterium labeled Dosimertinib (HY-142283). Dosimertinib is a highly potent, selective, and orally active deuterated EGFR inhibiotor. Dosimertinib can be used for the research of non-small-cell lung cancer[1][2].

HY-142283

Dosimertinib
Dosimertinib-d₃-d₃ is a potent and orally active EGFR inhibitor. Dosimertinib-d₃-d₃ decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₃-d₃ shows antiproliferative and anti-tumor activity. Dosimertinib-d₃-d₃ has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

Cat. No.	Product Name		Classification

HY-50896

Erlotinib 90+ Cited Publications CP-358774; NSC 718781; OSI-774		Alkynes
Erlotinib (CP-358774) is a directly acting EGFR tyrosine kinase inhibitor, with an IC₅₀ of 2 nM for human EGFR. Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC₅₀ of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer . Erlotinib is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-147858

PROTAC EGFR degrader 7		Alkynes
PROTAC EGFR degrader 7 (compound 13b) is a potent and selective CRBN-recruiting PROTAC EGFR ^L858R/T790M degrader, with a DC₅₀ of 13.2 nM. PROTAC EGFR degrader 7 inhibits NCI–H1975 cells proliferation, with an IC₅₀ of 46.82 nM. PROTAC EGFR degrader 7 significantly induces apoptosis and G2/M phase arrest in NCI–H1975 cell. PROTAC EGFR degrader 7 shows antitumor activity, and can be used for non-small cell lung cancer (NSCLC) research . PROTAC EGFR degrader 7 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks